|
Name |
2-(D-alanylamino)-N-[(1S)-1-hydroxy-3-mercaptopropyl]benzamide
|
| Molecular Formula | C13H19N3O3S | |
| IUPAC Name* |
2-[[(2R)-2-aminopropanoyl]amino]-N-[(1S)-1-hydroxy-3-sulfanylpropyl]benzamide
|
|
| SMILES |
C[C@H](C(=O)NC1=CC=CC=C1C(=O)N[C@H](CCS)O)N
|
|
| InChI |
InChI=1S/C13H19N3O3S/c1-8(14)12(18)15-10-5-3-2-4-9(10)13(19)16-11(17)6-7-20/h2-5,8,11,17,20H,6-7,14H2,1H3,(H,15,18)(H,16,19)/t8-,11+/m1/s1
|
|
| InChIKey |
DQGIXJCPVVNGMY-KCJUWKMLSA-N
|
|
| Synonyms |
fusarithioamide A; CHEMBL4576097; CHEBI:141359; 2-(D-alanylamino)-N-[(1S)-1-hydroxy-3-mercaptopropyl]benzamide; 2-(D-alanylamino)-N-[(1S)-1-hydroxy-3-sulfanylpropyl]benzamide
|
|
| CAS | NA | |
| PubChem CID | 134692099 | |
| ChEMBL ID | CHEMBL4576097 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 297.38 | ALogp: | 0.5 |
| HBD: | 5 | HBA: | 5 |
| Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 105.0 | Aromatic Rings: | 1 |
| Heavy Atoms: | 20 | QED Weighted: | 0.394 |
| Caco-2 Permeability: | -5.879 | MDCK Permeability: | 0.00000761 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.064 |
| Human Intestinal Absorption (HIA): | 0.019 | 20% Bioavailability (F20%): | 0.112 |
| 30% Bioavailability (F30%): | 0.914 |
| Blood-Brain-Barrier Penetration (BBB): | 0.418 | Plasma Protein Binding (PPB): | 61.08% |
| Volume Distribution (VD): | 0.842 | Fu: | 59.29% |
| CYP1A2-inhibitor: | 0.028 | CYP1A2-substrate: | 0.058 |
| CYP2C19-inhibitor: | 0.057 | CYP2C19-substrate: | 0.065 |
| CYP2C9-inhibitor: | 0.055 | CYP2C9-substrate: | 0.058 |
| CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.2 |
| CYP3A4-inhibitor: | 0.015 | CYP3A4-substrate: | 0.122 |
| Clearance (CL): | 7.189 | Half-life (T1/2): | 0.801 |
| hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.128 |
| Drug-inuced Liver Injury (DILI): | 0.392 | AMES Toxicity: | 0.116 |
| Rat Oral Acute Toxicity: | 0.041 | Maximum Recommended Daily Dose: | 0.023 |
| Skin Sensitization: | 0.318 | Carcinogencity: | 0.053 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
| Respiratory Toxicity: | 0.548 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003916 | ![]() |
0.375 | D06LYG | ![]() |
0.380 | ||
| ENC000684 | ![]() |
0.373 | D0RA5Q | ![]() |
0.361 | ||
| ENC001904 | ![]() |
0.364 | D0G2MH | ![]() |
0.329 | ||
| ENC004239 | ![]() |
0.358 | D0GY5Z | ![]() |
0.328 | ||
| ENC001804 | ![]() |
0.338 | D00DEF | ![]() |
0.321 | ||
| ENC005325 | ![]() |
0.329 | D01PJR | ![]() |
0.319 | ||
| ENC000073 | ![]() |
0.328 | D05OFX | ![]() |
0.316 | ||
| ENC000301 | ![]() |
0.324 | D07WXE | ![]() |
0.296 | ||
| ENC000055 | ![]() |
0.323 | D0SH3I | ![]() |
0.294 | ||
| ENC000717 | ![]() |
0.319 | D0A8XN | ![]() |
0.287 | ||